Development of acellular pertussis vaccines

Biologicals

Volumn 27, Issue 2, 1999, Pages 61-69

  Sato, Yuji ^a   Sato, Hiroko ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; FORMALDEHYDE; HEMAGGLUTININ; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ACTIVE IMMUNIZATION; DETOXIFICATION; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; JAPAN; PASSIVE IMMUNIZATION; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS;

EID: 0032726089     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0181     Document Type: Article

References (43)

1. Pittman M. History of the development of pertussis vaccine. Dev Biol Stand. 73:1991;13-29.
2. Kendrick PL, Eldering G, Dixon MK. Mouse protection tests in the study of pertussis vaccine-A comparative series using the intracerebral route for challenge. Am. J. Public Health. 37:1947;803-810.
3. Br Med J. I:1951;1463-1471.
4. Br Med J. 2:1956;454-462.
5. Br Med J. I:1959;994-1000.
6. Felton HM, Verwey WF. The epidemiological evaluation of a non-cellular pertussis antigen. Pediatrics. 16:1955;637-651.
7. Sato Y, Sato H. Pertussis vaccine. Vaccine Handbook (Researcher's Associates, The National Institute of Health. 1996;Maruzen, Tokyo. p. 39-51.
8. Sato H, Takahashi M. Diphtheria toxoid (Diphtheria vaccine). Vaccine Handbook (Researcher's Associates, The National Institute of Health. 1996;Maruzen, Tokyo. p. 52-59.
9. Sato H, Takahashi M. Tetanus toxid (Tetanus vaccine). Vaccine Handbook (Researcher's Associates, The National Institute of Health. 1996;Maruzen, Tokyo. p. 60-67.
10. Sato Y, Sato H. Diphtheria, Tetanus, and Pertussis (DTP) Combined Vaccine. Vaccine Handbook, (Researcher's Associates, The National Institute of Health. 1996;Maruzen, Tokyo. p. 68-71.
11. Sato Y, Arai H. Leukocytosis-promoting factor of Bordetella pertussis. I. Purification and characterization. Infect Immun. 6:1972;899-904.
12. Sato Y, Arai H, Suzuki K. Leukocytosis-promoting factor of Bordetella pertussis. II. Biological properties. Infect Immun. 7:1973;992-999.
13. Sato Y, Arai H, Suzuki K. Leukocytosis-promoting factor from Bordetella pertussis. III: Its identity with protective antigen. Infect Immun. 9:1974;801-810.
14. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. i:1984;122-126.
15. Lancet. i:1988;955-960.
16. Olin, P, Storsaeter, J, The efficacy of two acellular pertussis vaccines (JNIH-6 & JNIH-7) during 3 years of post trial follow up. Report from the Department of Pediatrics, Sach's Children's Hospital, Karolinska Institute and Nat. Bacteriol. Lab, Stockholm, Sweden, Interim. Report 1, December, 1990.
17. Blackwelder WC, Storsaeter J, Olin P. Acellular pertussis vaccine - efficacy and evaluation of clinical case definition. Am J Dis Child. 145:1991;1285-1289.
18. JAMA. 267:1992;485.
19. MMWR. 41:1992;1-10.
20. MMWR. 41:1992;1-5.
21. Arai H, Sato Y. Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor fromBordetella pertussis. Biochim Biophys Acta. 444:1976;765-786.
22. Ministry of Health and Welfare of Japan, Minimum Requirement for Biological Products, Adsorbed Purified Pertussis Vaccine, 130, 135, Association of Biological Manufacturers of Japan, Tokyo, 1986.
23. Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin and filamentous hemagglutinin with mouse protectivity in intracerebral or aerosol challenge system. Infect Immun. 46:1984;415-421.
24. Sato H, Ito A, Chiba J, Sato Y. Monoclonal antibody against pertussis toxin: Effect on toxin activity and pertussis infection. Infect Immun. 46:1984;422-428.
25. Sato H, Sato Y. Protective antigens of Bordetella pertussis. Mouse protection test against intracerebral and aerosol challenge of B. pertussis. Dev Biol Stand. 61:1984;461-476.
26. Sato H, Sato Y. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun. 58:1990;3369-3374.
27. Sato H, Sato Y, Ohishi I. Comparison of Pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect Immun. 59:1991;3832-3835.
28. Sato Y, Sato H. Characterization of mutant strains producing pertussis toxin CRMs. Dev Biol Stand. 73:1991;93-107.
29. Locht C, Keith JM. Pertussis toxin gene: Nucleotide sequence and genetic organization. Science. 232:1986;1258-1264.
30. Nicosia A, Perugini M, Franzini C. Cloning and sequencing of the pertussis toxin genes: Operon structure and gene duplication. Proc Natl Acad Sci U S A. 83:1986;4631-4635.
31. Relman DA, Domenighini M, Tuomanen E, Rappuoli R, Falkow S. Filamentous hemagglutinin of Bordetella pertussis: Nucleotide sequence and crucial role in adherence. Proc Natl Acad Sci U S A. 86:1989;2637-2641.
32. Guiso N, Szatanik M, Rocancourt M. Protective activity of Bordetella adenylate cyclase - hemolysis against bacterial colonization. Microb Pathog. 11:1991;423-431.
33. Shahin RD. Characterization of the protective capacity and immunogenicity of the 69-kd outer membrane protein of Bordetella pertussis. J Exp Med. 171:1990;63-73.
34. Goldman WE. Tracheal cytotoxin of Bordetella pertussis. Wardlaw AC, Parton R. Pathogenesis and Immunity in Pertussis. 1988;231-246 Wiley, Chichester.
35. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M, Giovannoni F, Olivieri R, Barbieri JT, Sato H, Rappuoli R. Mutants of pertussis toxin suitable for vaccine development. Science. 246:1989;497-500.
36. Brown DR, Keith JM, Sato H, Sato Y. Construction and characterization of genetically inactivated pertussis toxin. Dev Biol Stand. 73:1991;63-73.
37. Lobet Y, Feron C, Dequesne G, Simoen E, Hauser P, Locht C. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin. J Exp Med. 177:1993;79-87.
38. Nencioni L, Pizza M, Bugnoli M. Characterization of genetically inactivated pertussis toxin mutants: Candidates for a new vaccine against whooping cough. Infect Immun. 58:1990;1308-1315.
39. Kimura M, Kuno-Sakai H. Current epidemiology of pertusis in Japan. Pediatr Infect Dis J. 9:1990;705-709.
40. Kimura M, Kuno-Sakai H. Developments in pertussis immunization in Japan. Lancet. 336:1990;30-32.
41. Sakai, H, Kimura, M, Modern Perspectives of Child Neurology, 1991, 1, 141, 147.
42. Sato Y, Sato H. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J Expl Clin Med. 13:1988;79-88.
43. Cherry JD, Baraff LJ, Hewlett E. The past, present and future of pertussis. The role of adults in epidemiology and future control. West J Med. 150:1989;319-328.